AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03549715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV D1 every 28 days ((2 doses for each patient)
Study NCT01080898 — intervention group
Intervention type: OTHER
Intervention: tests
Description: color photographs, FLUORESCEIN angiography and OCT
Study NCT03365700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
Study NCT03549715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVAC Protocol
Description: 1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1
Study NCT02891382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes education
Description: Participants interact with a diabetes educator (DE), every two weeks.
Study NCT02891382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting
Description: Goals for weight loss and change in levels of HbA1c
Study NCT02891382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Companion Support
Description: Patient has a companion/team support partner to support achieving goals.
Study NCT02891382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Reward
Description: The cash reward is given to the patient with diabetes.
Study NCT02891382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Reward
Description: Patients with diabetes and their companion support will each receive 50% of the cash reward.
Study NCT03679026 — intervention group
Intervention type: OTHER
Intervention: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Description: Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
Study NCT00961714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoFix Spinal Fracture Reduction System
Description: All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
Study NCT03365700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
Study NCT05735301 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA
Study NCT00693524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT00693524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: oral
Study NCT00693524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IL2R AB
Description: i.v.
Study NCT05735301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug
Description: best drug conservative therapy could be uesd in patients who with no indication of surgery
Study NCT00723359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT062
Description: biologic
Study NCT06430723 — intervention group
Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
Study NCT00644111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine, Hydromorphone
Description: 0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
Study NCT00644111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
Study NCT03244826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Care
Description: Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
Study NCT03244826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: The usual care provided by the transplant center at DFCI.
Study NCT03080636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30 minutes of treadmill exercise at 60-70% of heart rate reserve
Study NCT00693524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: oral
Study NCT00693524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral
Study NCT03080636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 30 minutes of circuit resistance session at 40% of 1 maximun repetition test
Study NCT03080636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control session
Description: 30 minutes seated resting
Study NCT04356040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiFlex SE
Description: Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
Study NCT04177940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMAB Discontinuation and Switching
Description: Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose
Study NCT04356040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiFlex SE - High Standard Power
Description: Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
Study NCT01836926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open intersphincteric resection
Description: laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
Study NCT01836926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transanal minimally invasive intersphincteric resection
Description: minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
Study NCT02014779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eChange
Description: A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
Study NCT02014779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face therapy
Description: Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
Study NCT00697710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg S-777469
Description: S-777469, 50 mg BID
Study NCT00697710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg S-777469
Description: S-777469, 200 mg BID
Study NCT00697710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg S-777469
Description: S-777469, 800 mg BID
Study NCT00697710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT01008904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium oxide
Description: Given PO
Study NCT01008904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01008904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02243891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Percutaneous catheter ablation for Atrial fibrillation.
Study NCT02243891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Percutaneous catheter ablation for Atrial fibrillation.
Study NCT02243891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROX Coupler insertion
Description: The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
Study NCT04330027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth factors
Description: A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
Study NCT04330027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Sodium Chloride
Study NCT04394650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC-98633
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection.
Study NCT00336557 — intervention group
Intervention type: PROCEDURE
Intervention: NAbs testing
Description: blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
Study NCT02355444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: blackberry polyphenol enriched beverage
Description: Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
Study NCT02355444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: blackberry beverage with minimal polyphenol concentrations
Description: Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
Study NCT01138501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
Study NCT01138501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
Study NCT03815565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous femoral block
Description: infusion of anesthetic by PCA pump
Study NCT03815565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous femoral block
Description: infusion of anesthetic by PCA pump
Study NCT02073019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Study NCT02073019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02294344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFPP&CTX
Description: First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented.
Study NCT02294344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study.
Study NCT00263068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day
Study NCT03571581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Description: Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
Study NCT00729183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
Study NCT00729183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
Study NCT00729183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
Study NCT00729183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
Study NCT00729183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
Study NCT00729183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium supplement
Description: Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
Study NCT02331147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment
Study NCT02331147 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment
Study NCT02331147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing Application
Description: Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
Study NCT03657095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esuberaprost
Description: Sodium tablets
Study NCT03657095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esuberaprost
Description: Sodium tablets
Study NCT03657095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
Study NCT01381549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem-cilastatin
Description: Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
Study NCT01381549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline placebo
Study NCT01381549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: saline placebo
Study NCT02917148 — intervention group
Intervention type: OTHER
Intervention: Peripheral Venipuncture or Blood draw from Central Line
Study NCT01455779 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lyrette
Description: The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment.
Study NCT02441829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally in morning with food
Study NCT00824057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: oral
Study NCT00824057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral
Study NCT00824057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral
Study NCT04776122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Device-assisted breathing for relaxation
Study NCT04776122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No device
Description: Breathing platform without device
Study NCT02723799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hope Promotion Program (HPP)
Description: HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families.
Study NCT02723799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment Protocol
Description: Regular assessment and care by the hospital outpatient health care team.
Study NCT02723799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment Protocol
Description: Regular assessment and care by the hospital outpatient health care team.
Study NCT03425175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-recoring
Description: Recording of audio through microphone carried bu surgeon and assistant surgeon
Study NCT00690313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox
Description: eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Study NCT03688087 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Smartphone application placebo
Description: Strategy based on smartphone application placebo
Study NCT03688087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone equipped with application bouge = Coach group
Description: Strategy based on smartphone application bouge
Study NCT01236898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-09
Description: NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)